Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

Date

21 Oct 2018

Session

Poster Discussion session - Breast cancer, metastatic

Presenters

MING-SHEN DAI

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

M. DAI1, T. Chao2, T. Chao3, C. Chiu4, Y. Lu5, H. Shiah6, Y. Wu1, G. Gerald Fetterly7, N. Hung8, D.L. Cutler7, R. Kwan7, D. Douglas Kramer7, W. Chan7, T. Hung9

Author affiliations

  • 1 Hematology/oncology, Tri-Service General Hospital, National Defense Medical Center, 11490 - Taipei/TW
  • 2 Division Of Hematology-oncology,, Taipei Medical University- Shuang Ho Hospital, No. 291, Zhongzheng Rd., Zhonghe District, New Taipei City, 23561, 23561 - NewTaipei/TW
  • 3 Medical Oncology, Taipei Veterans General Hospital, Taipei, 11217 - Taipei/TW
  • 4 Hematology/oncology, China Medical University Hospital, Tai-Chung/TW
  • 5 Hematology/oncology, National Taiwan University Hospital, Taipei/TW
  • 6 Hematology/oncology, Taipei Medical University Hospital, Taipei/TW
  • 7 Athenex, Athenex, 14203 - New York/US
  • 8 University Of Otago, University of Otago , 9054 - Dunedin/NZ
  • 9 Zenith Technology Corporation Limited, Zenith Technology Corporation Limited, 9054 - Dunedin/NZ
More

Resources

Background

Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

Methods

Multicenter, single-arm, open-label, study of Oraxol (HM30181A at 15mg, plus oral paclitaxel 205mg/m2) administered orally for 3 consecutive days/week for up to 16 weeks. Paclitaxel PK was determined in the first and fourth week of Oraxol. Tumor Response by CT/MRI was measured using RECIST criteria 1.1 at weeks 8 and 16.

Results

Sixteen MBC patients have been enrolled with a mean (range) age of 56.9 years (range: 38 - 79 yrs). Most had previous combination chemotherapies and/or monotherapy. There were seven (50%) partial responses and 7 (50%) with stable disease in 14 evaluable patients who had post-treatment CT scans. There was no progressive disease for the patients that reached 16 weeks of treatment. Three patients had treatment-related SAEs (grade ≥3 neutropenia); and there was 1 non-treatment related death. Preliminary PK results showed that the daily mean AUC of oral paclitaxel was similar at week-1 and week-4 (1397 vs. 1137 ng-hr/mL). Other studies have shown that oral paclitaxel can achieve exposure similar to that of IV paclitaxel.

Conclusions

Oral paclitaxel showed very encouraging activity in MBC patients with acceptable toxicity. PK of oral paclitaxel is reproducible.

Clinical trial identification

NCT03165955.

Legal entity responsible for the study

The authors.

Funding

Athenex, Buffalo, NY.

Editorial Acknowledgement

Disclosure

G. Gerald Fetterly, D.L. Cutler, R. Kwan, D. Douglas Kramer, W-K. Chan: Sockholder and employee: Athenex. T. Hung: Stockholder: Athenex. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings